The Friday Gospel
A concise briefing separating revelation from rumor: regulatory decisions, scientific advances, safety signals, industry movements, and the candidates approaching the doors of the canon.
New · November 6, 2026 — Read the latest dispatch →The Ledger and the Laboratory
RFK Jr.’s peptide-access position, HHS policy, human and preclinical research, and company disclosures—with evidence limits.
Access Is Not Approval
HHS peptide policy, sponsor-reported retatrutide results and market disclosures—with access, approval and clinical evidence kept separate.
Progress Is Not Permission
Peptide policy, Yuviwel’s European recommendation, exploratory CagriSema findings, safety follow-up and manufacturing news—with evidence limits.
Retatrutide: Reports Are Signals, Not Verdicts
Retatrutide safety reports, psoriasis follow-up, early brain-tumor delivery evidence and peptide-sector financing—with clear evidence limits.
Petrelintide: A New Result, Not a Final Verdict
Petrelintide trial results, longer-term psoriasis evidence and the limits of laboratory promise.
Retatrutide Enters the Full Record
Two statistical estimates, investigational combination results and the Nanexa–Novo delivery agreement.
FDA Approves Onswik
FDA approval for adults with type 2 diabetes, with important safety boundaries and new investigational trial results.
The Wolverine Gap
BPC-157 adoption is rising faster than controlled human evidence, while regulators and researchers weigh an incomplete record.
Semaglutide Enters a Younger Trial
A company-reported phase 3 trial in children met its primary endpoint. That is controlled human evidence—not a new approval.
Tirzepatide Meets Immunology
Lilly reported one-year phase 3b results combining tirzepatide with ixekizumab in adults with psoriatic disease and obesity.
A Faster Road to First-in-Human?
Novo Nordisk and AWS announced an AI and cloud partnership aimed at compressing drug discovery timelines.
The GLP-1 Ledger Expands
Novo Nordisk’s quarterly report tied GLP-1 volume growth to sales and described European regulatory milestones for Wegovy formulations.